IL268689B2 - Fused imidazo-piperidine jak inhibitors - Google Patents
Fused imidazo-piperidine jak inhibitorsInfo
- Publication number
- IL268689B2 IL268689B2 IL268689A IL26868919A IL268689B2 IL 268689 B2 IL268689 B2 IL 268689B2 IL 268689 A IL268689 A IL 268689A IL 26868919 A IL26868919 A IL 26868919A IL 268689 B2 IL268689 B2 IL 268689B2
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- compound
- nitrogen atom
- ethyl
- pharmaceutically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469073P | 2017-03-09 | 2017-03-09 | |
| PCT/US2018/021492 WO2018165395A1 (en) | 2017-03-09 | 2018-03-08 | Fused imidazo-piperidine jak inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL268689A IL268689A (en) | 2019-10-31 |
| IL268689B IL268689B (en) | 2022-10-01 |
| IL268689B2 true IL268689B2 (en) | 2023-02-01 |
Family
ID=61683956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268679A IL268679B (en) | 2017-03-09 | 2019-08-13 | JAK inhibitors containing a tetracyclic heterocyclic amide |
| IL268689A IL268689B2 (en) | 2017-03-09 | 2019-08-13 | Fused imidazo-piperidine jak inhibitors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268679A IL268679B (en) | 2017-03-09 | 2019-08-13 | JAK inhibitors containing a tetracyclic heterocyclic amide |
Country Status (20)
| Country | Link |
|---|---|
| US (10) | US10208040B2 (enExample) |
| EP (2) | EP3592742B1 (enExample) |
| JP (2) | JP6974487B2 (enExample) |
| KR (2) | KR102533646B1 (enExample) |
| CN (2) | CN110461839B (enExample) |
| AR (2) | AR111241A1 (enExample) |
| AU (2) | AU2018231032B2 (enExample) |
| BR (2) | BR112019018649A2 (enExample) |
| CA (1) | CA2997772A1 (enExample) |
| DK (1) | DK3592742T3 (enExample) |
| EA (2) | EA037748B1 (enExample) |
| ES (1) | ES2882186T3 (enExample) |
| IL (2) | IL268679B (enExample) |
| MX (2) | MX388749B (enExample) |
| PH (2) | PH12019501941A1 (enExample) |
| PT (1) | PT3592742T (enExample) |
| SG (2) | SG11201907840RA (enExample) |
| TW (2) | TWI754019B (enExample) |
| WO (2) | WO2018165395A1 (enExample) |
| ZA (2) | ZA201905585B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017079205A1 (en) | 2015-11-03 | 2017-05-11 | Theravance Biopharma R&D Ip, Llc | Jak kinase inhibitor compounds for treatment of respiratory disease |
| WO2017077288A1 (en) * | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| JP6974487B2 (ja) | 2017-03-09 | 2021-12-01 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ４員ヘテロ環式アミドを含むｊａｋ阻害剤 |
| US10406148B2 (en) | 2017-05-01 | 2019-09-10 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| BR112021004052A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas de dimetil-amino azetidina como inibidores de jak |
| WO2020051135A1 (en) | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
| SG11202101751XA (en) * | 2018-09-04 | 2021-03-30 | Theravance Biopharma R&D Ip Llc | 5 to 7 membered heterocyclic amides as jak inhibitors |
| MX2021004582A (es) * | 2018-10-29 | 2021-06-15 | Theravance Biopharma R&D Ip Llc | Compuesto 2-azabiciclo hexano inhibidor de jak. |
| MX2021010242A (es) | 2019-02-25 | 2021-09-21 | Henan Medinno Pharmaceutical Tech Co Ltd | Compuesto inhibidor de jak y uso del mismo. |
| JP2022524997A (ja) | 2019-03-05 | 2022-05-11 | インサイト・コーポレイション | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
| EP4065578A1 (en) * | 2019-11-26 | 2022-10-05 | Theravance Biopharma R&D IP, LLC | Fused pyrimidine pyridinone compounds as jak inhibitors |
| CN113121509B (zh) * | 2019-12-30 | 2024-04-26 | 河南迈英诺医药科技有限公司 | Jak抑制剂化合物及其用途 |
| TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| WO2022178215A1 (en) * | 2021-02-19 | 2022-08-25 | Theravance Biopharma R&D Ip, Llc | Amino amide tetrahydro imidazo pyridines as jak inhibitors |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| PE20241589A1 (es) * | 2021-12-17 | 2024-08-01 | Daewoong Pharmaceutical Co Ltd | Nueva sal de adicion de acido y ofrma cristalina de (2r,3s)-2-(3-(4,5-dicloro-1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol |
| CN117658852A (zh) * | 2023-11-15 | 2024-03-08 | 西北工业大学 | 取代苯氧乙酰肼类化合物及其制备方法和作为stat3的抗炎抑制剂的应用 |
| WO2025157904A1 (en) * | 2024-01-24 | 2025-07-31 | Kiox Pharmaceuticals Aps | Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof |
| CN118903009B (zh) * | 2024-10-11 | 2025-01-21 | 江苏长泰药业股份有限公司 | 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013014567A1 (en) * | 2011-07-27 | 2013-01-31 | Pfizer Limited | Indazoles |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7872014B2 (en) | 2003-07-23 | 2011-01-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| US20120029190A1 (en) | 2009-04-03 | 2012-02-02 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| LT3001903T (lt) | 2009-12-21 | 2018-01-10 | Samumed, Llc | 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas |
| EP2338888A1 (en) * | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| WO2013060636A1 (en) | 2011-10-25 | 2013-05-02 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| MD4649C1 (ro) | 2013-12-05 | 2020-04-30 | Pfizer Inc. | Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide |
| PE20161475A1 (es) | 2014-05-14 | 2017-01-08 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| EP3712152B1 (en) | 2015-11-03 | 2021-01-13 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| WO2017077288A1 (en) * | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| WO2017079205A1 (en) | 2015-11-03 | 2017-05-11 | Theravance Biopharma R&D Ip, Llc | Jak kinase inhibitor compounds for treatment of respiratory disease |
| JP6974487B2 (ja) * | 2017-03-09 | 2021-12-01 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ４員ヘテロ環式アミドを含むｊａｋ阻害剤 |
| US10406148B2 (en) | 2017-05-01 | 2019-09-10 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| TWI808083B (zh) | 2017-05-01 | 2023-07-11 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶型式 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| KR102032418B1 (ko) | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| SG11202101751XA (en) | 2018-09-04 | 2021-03-30 | Theravance Biopharma R&D Ip Llc | 5 to 7 membered heterocyclic amides as jak inhibitors |
| WO2020051135A1 (en) | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
| BR112021004052A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas de dimetil-amino azetidina como inibidores de jak |
-
2018
- 2018-03-08 JP JP2019548449A patent/JP6974487B2/ja active Active
- 2018-03-08 MX MX2019010539A patent/MX388749B/es unknown
- 2018-03-08 AR ARP180100542A patent/AR111241A1/es not_active Application Discontinuation
- 2018-03-08 DK DK18711796.5T patent/DK3592742T3/da active
- 2018-03-08 EA EA201992128A patent/EA037748B1/ru unknown
- 2018-03-08 EA EA201992126A patent/EA037261B1/ru not_active IP Right Cessation
- 2018-03-08 MX MX2019010541A patent/MX388750B/es unknown
- 2018-03-08 TW TW107107939A patent/TWI754019B/zh not_active IP Right Cessation
- 2018-03-08 PT PT187117965T patent/PT3592742T/pt unknown
- 2018-03-08 JP JP2019548369A patent/JP7134990B2/ja active Active
- 2018-03-08 ES ES18711796T patent/ES2882186T3/es active Active
- 2018-03-08 AU AU2018231032A patent/AU2018231032B2/en not_active Ceased
- 2018-03-08 WO PCT/US2018/021492 patent/WO2018165395A1/en not_active Ceased
- 2018-03-08 CA CA2997772A patent/CA2997772A1/en active Pending
- 2018-03-08 WO PCT/US2018/021489 patent/WO2018165392A1/en not_active Ceased
- 2018-03-08 US US15/915,434 patent/US10208040B2/en active Active
- 2018-03-08 TW TW107107936A patent/TWI779016B/zh not_active IP Right Cessation
- 2018-03-08 US US15/915,418 patent/US10196393B2/en active Active
- 2018-03-08 CN CN201880017046.0A patent/CN110461839B/zh active Active
- 2018-03-08 SG SG11201907840RA patent/SG11201907840RA/en unknown
- 2018-03-08 EP EP18711796.5A patent/EP3592742B1/en active Active
- 2018-03-08 EP EP18712398.9A patent/EP3592743A1/en not_active Withdrawn
- 2018-03-08 KR KR1020197029543A patent/KR102533646B1/ko active Active
- 2018-03-08 AR ARP180100543A patent/AR111242A1/es unknown
- 2018-03-08 CN CN201880016693.XA patent/CN110382498B/zh not_active Expired - Fee Related
- 2018-03-08 BR BR112019018649A patent/BR112019018649A2/pt not_active IP Right Cessation
- 2018-03-08 SG SG11201907544VA patent/SG11201907544VA/en unknown
- 2018-03-08 AU AU2018231035A patent/AU2018231035B2/en not_active Ceased
- 2018-03-08 KR KR1020197029560A patent/KR102526764B1/ko active Active
- 2018-03-08 BR BR112019018648-4A patent/BR112019018648A2/pt not_active IP Right Cessation
- 2018-12-17 US US16/222,647 patent/US10392386B2/en active Active
- 2018-12-19 US US16/225,473 patent/US10519153B2/en active Active
-
2019
- 2019-07-15 US US16/511,410 patent/US10550118B2/en active Active
- 2019-08-13 IL IL268679A patent/IL268679B/en unknown
- 2019-08-13 IL IL268689A patent/IL268689B2/en unknown
- 2019-08-22 PH PH12019501941A patent/PH12019501941A1/en unknown
- 2019-08-23 ZA ZA2019/05585A patent/ZA201905585B/en unknown
- 2019-08-26 ZA ZA2019/05618A patent/ZA201905618B/en unknown
- 2019-08-29 PH PH12019501985A patent/PH12019501985A1/en unknown
- 2019-11-11 US US16/679,676 patent/US11254669B2/en active Active
- 2019-12-03 US US16/701,426 patent/US10954237B2/en active Active
-
2021
- 2021-02-12 US US17/248,907 patent/US11453668B2/en active Active
-
2022
- 2022-01-14 US US17/576,089 patent/US11667637B2/en active Active
- 2022-08-10 US US17/885,475 patent/US11878977B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013014567A1 (en) * | 2011-07-27 | 2013-01-31 | Pfizer Limited | Indazoles |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11667637B2 (en) | Fused imidazo-piperidine JAK inhibitors | |
| US11713315B2 (en) | 5 to 7 membered heterocyclic amides as JAK inhibitors | |
| US20250034131A1 (en) | Dimethyl amino azetidine amides as jak inhibitors | |
| CA3053853A1 (en) | Dimethyl amino azetidine amides and 5 to 7 membered heterocyclic amides as jak inhibitors | |
| NZ756823B2 (en) | Jak inhibitors containing a 4-membered heterocyclic amide |